propranolol has been researched along with Laryngeal Neoplasms in 47 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five cases of subglottic hemangioma treated with systemic propranolol are presented." | 8.98 | [Tiempo de respuesta terapéutica al propranolol sistémico en el manejo de hemangiomas subglóticos pediátricos: serie de casos y revisión de la literatura]. ( Álvarez-Neri, H; Morera-Serna, E; Penchyna-Grub, J; Teyssier-Morales, G; Torre, C; Villamor, P, 2018) |
| "Propranolol is rapidly becoming the standard of care in the treatment of subglottic hemangiomas." | 8.93 | The use of propranolol in the treatment of subglottic hemangiomas: A literature review and meta-analysis. ( Dodson, KM; Hardison, S; Wan, W, 2016) |
| "A literature search of Ovid, Embase, the Cochrane database, Google™ Scholar, and Medline using PubMed as the search engine was performed to identify studies that analysed the effect of propranolol treatment in children with airway haemangiomas." | 8.87 | A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. ( Athanasopoulos, I; Parpounas, K; Peridis, S; Pilgrim, G, 2011) |
| "The objective of this study is to describe the initial use of propranolol as the sole treatment for focal infantile airway hemangiomas, and to report on available literature describing the use of propranolol for airway lesions." | 8.86 | Initial experience using propranolol as the sole treatment for infantile airway hemangiomas. ( Hartnick, C; Maturo, S, 2010) |
| "The use of propranolol for the treatment of subglottic haemangioma has become hugely popular due to its effectiveness and safety profile." | 7.91 | Treatment failure with propranolol for subglottic haemangioma. ( Jackson, C; Liu, Z; Trimble, K; Yeo, YH, 2019) |
| "Oral propranolol is a safe and effective treatment for infantile subglottic hemangiomata and may be used as a first-line therapeutic modality." | 7.83 | Role of oral propranolol in the treatment of infantile subglottic hemangioma. ( Chen, JR; Jin, L; Li, XY; Wang, Y, 2016) |
| "Fifty percent of patients in our series did not have long-term response to propranolol for subglottic hemangioma, highlighting the importance of close follow-up." | 7.81 | Open airway surgery for subglottic hemangioma in the era of propranolol: Is it still indicated? ( Mehta, D; Siegel, B, 2015) |
| "To evaluate the effectiveness of systemic propranolol in airway infantile hemangioma (AIH) treatment." | 7.81 | Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas. ( Darrow, DH; Elluru, RG; Friess, MR; Grimmer, JF; Perkins, JA; Richter, GT; Shin, JJ, 2015) |
| "Recent reports of dramatic responses to oral propranolol in children with haemangioma and acute airway obstruction have led to increased use." | 7.79 | Great Ormond Street Hospital treatment guidelines for use of propranolol in infantile isolated subglottic haemangioma. ( Albert, DM; Bajaj, Y; Harper, JI; Hartley, BE; Ifeacho, S; Jephson, CG; Kapoor, K, 2013) |
| "Oral propranolol is a safe and effective treatment for infantile subglottic hemangioma." | 7.78 | [Treatment of infantile subglottic hemangioma with oral propranolol]. ( Tang, LX; Wang, GX; Zhang, YM, 2012) |
| "We performed a retrospective chart review with a 6-month follow-up to examine the initial use of propranolol as an adjunctive treatment in children with severe recurrent respiratory papillomatosis." | 7.77 | Initial experience using propranolol as an adjunctive treatment in children with aggressive recurrent respiratory papillomatosis. ( Hartnick, CJ; Kinane, TB; Maturo, S; Tse, SM, 2011) |
| "There has been a dramatic evolution in the treatment of laryngotracheal hemangiomas during the past decade and recent accounts and case reports of propranolol treatment have been encouraging." | 7.77 | Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery? ( Jacobs, IN; Javia, LR; Zur, KB, 2011) |
| "This preliminary nation-wide survey confirms propranolol high effectiveness against airways' localization of infantile hemangiomas." | 7.76 | Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience. ( Ayari, S; Carrabin, L; Couloigner, V; Cox, A; Denoyelle, F; Fayoux, P; Froehlich, P; Garabédian, EN; Leboulanger, N; Lescanne, E; Marianowski, R; Marie, JP; Mom, T; Mondain, M; Nicollas, R; Roger, G; Teissier, N; Triglia, JM; Van Den Abbeele, T, 2010) |
| "Seven patients presenting with airway obstruction were treated with propranolol." | 7.76 | Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm. ( Chang, KW; Messner, AH; Perkins, JA; Truong, MT, 2010) |
| "The successful management of subglottic hemangioma with propranolol has been reported." | 7.76 | Management of infantile subglottic hemangioma: acebutolol or propranolol? ( Amedro, P; Bigorre, M; Blanchet, C; Mondain, M; Nicollas, R, 2010) |
| " She was given propranolol after her tracheotomy and had a significant reduction in her subglottic airway obstruction." | 7.76 | Propranolol in the management of airway infantile hemangiomas. ( Frieden, IJ; Maguiness, SM; Meyer, AK; Rosbe, KW; Suh, KY, 2010) |
| "Prior to propranolol treatment, laryngotracheobronchoscopy revealed an extensive haemangioma extending from the posterior pharyngeal wall to the subglottis." | 7.76 | Use of propranolol to treat multicentric airway haemangioma. ( Mistry, N; Tzifa, K, 2010) |
| "There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol." | 7.75 | Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. ( Denoyelle, F; Enjolras, O; Garabedian, EN; Harris, R; Leboulanger, N; Roger, G, 2009) |
| "Infantile hemangioma is one of the most common benign tumors of infancy." | 6.72 | Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review. ( Ganeva, K; Nikiforova, L; Sapundzhiev, N; Shivachev, P, 2021) |
| "Subglottic haemangioma is a rare but potentially life threatening condition which requires intervention." | 5.35 | Successful treatment of isolated subglottic haemangioma with propranolol alone. ( Harper, J; Hartley, BE; Jephson, CG; Manunza, F; Mills, NA; Syed, S, 2009) |
| "Five cases of subglottic hemangioma treated with systemic propranolol are presented." | 4.98 | [Tiempo de respuesta terapéutica al propranolol sistémico en el manejo de hemangiomas subglóticos pediátricos: serie de casos y revisión de la literatura]. ( Álvarez-Neri, H; Morera-Serna, E; Penchyna-Grub, J; Teyssier-Morales, G; Torre, C; Villamor, P, 2018) |
| "Propranolol is rapidly becoming the standard of care in the treatment of subglottic hemangiomas." | 4.93 | The use of propranolol in the treatment of subglottic hemangiomas: A literature review and meta-analysis. ( Dodson, KM; Hardison, S; Wan, W, 2016) |
| "A literature search of Ovid, Embase, the Cochrane database, Google™ Scholar, and Medline using PubMed as the search engine was performed to identify studies that analysed the effect of propranolol treatment in children with airway haemangiomas." | 4.87 | A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. ( Athanasopoulos, I; Parpounas, K; Peridis, S; Pilgrim, G, 2011) |
| "The objective of this study is to describe the initial use of propranolol as the sole treatment for focal infantile airway hemangiomas, and to report on available literature describing the use of propranolol for airway lesions." | 4.86 | Initial experience using propranolol as the sole treatment for infantile airway hemangiomas. ( Hartnick, C; Maturo, S, 2010) |
| "The use of propranolol for the treatment of subglottic haemangioma has become hugely popular due to its effectiveness and safety profile." | 3.91 | Treatment failure with propranolol for subglottic haemangioma. ( Jackson, C; Liu, Z; Trimble, K; Yeo, YH, 2019) |
| "Oral propranolol is a safe and effective treatment for infantile subglottic hemangiomata and may be used as a first-line therapeutic modality." | 3.83 | Role of oral propranolol in the treatment of infantile subglottic hemangioma. ( Chen, JR; Jin, L; Li, XY; Wang, Y, 2016) |
| "To evaluate the effectiveness of systemic propranolol in airway infantile hemangioma (AIH) treatment." | 3.81 | Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas. ( Darrow, DH; Elluru, RG; Friess, MR; Grimmer, JF; Perkins, JA; Richter, GT; Shin, JJ, 2015) |
| "Fifty percent of patients in our series did not have long-term response to propranolol for subglottic hemangioma, highlighting the importance of close follow-up." | 3.81 | Open airway surgery for subglottic hemangioma in the era of propranolol: Is it still indicated? ( Mehta, D; Siegel, B, 2015) |
| "Recent reports of dramatic responses to oral propranolol in children with haemangioma and acute airway obstruction have led to increased use." | 3.79 | Great Ormond Street Hospital treatment guidelines for use of propranolol in infantile isolated subglottic haemangioma. ( Albert, DM; Bajaj, Y; Harper, JI; Hartley, BE; Ifeacho, S; Jephson, CG; Kapoor, K, 2013) |
| " The beta-blocker propranolol, known for its effectiveness on cutaneous hemangiomas, is also proving useful for the treatment of subglottic or visceral hemangiomas." | 3.78 | [Pediatrics]. ( Chevallay, M; de Buys Roessingh, A; El Ezzi, O; Fischer, CJ; Gehri, M; Giannoni, E; Hauschild, M; Hohlfeld, J; Pauchard, JY; Seneggen, E; Tolsa, JF; Truttmann, AC, 2012) |
| "Oral propranolol is a safe and effective treatment for infantile subglottic hemangioma." | 3.78 | [Treatment of infantile subglottic hemangioma with oral propranolol]. ( Tang, LX; Wang, GX; Zhang, YM, 2012) |
| "Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers." | 3.77 | β-blockers for infantile hemangiomas: a single-institution experience. ( Blatt, J; Buck, S; Burkhart, CN; Gold, S; Morrell, DS; Powell, C; Stavas, J; Zdanski, C, 2011) |
| "There has been a dramatic evolution in the treatment of laryngotracheal hemangiomas during the past decade and recent accounts and case reports of propranolol treatment have been encouraging." | 3.77 | Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery? ( Jacobs, IN; Javia, LR; Zur, KB, 2011) |
| "We performed a retrospective chart review with a 6-month follow-up to examine the initial use of propranolol as an adjunctive treatment in children with severe recurrent respiratory papillomatosis." | 3.77 | Initial experience using propranolol as an adjunctive treatment in children with aggressive recurrent respiratory papillomatosis. ( Hartnick, CJ; Kinane, TB; Maturo, S; Tse, SM, 2011) |
| "Prior to propranolol treatment, laryngotracheobronchoscopy revealed an extensive haemangioma extending from the posterior pharyngeal wall to the subglottis." | 3.76 | Use of propranolol to treat multicentric airway haemangioma. ( Mistry, N; Tzifa, K, 2010) |
| "Seven patients presenting with airway obstruction were treated with propranolol." | 3.76 | Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm. ( Chang, KW; Messner, AH; Perkins, JA; Truong, MT, 2010) |
| "This preliminary nation-wide survey confirms propranolol high effectiveness against airways' localization of infantile hemangiomas." | 3.76 | Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience. ( Ayari, S; Carrabin, L; Couloigner, V; Cox, A; Denoyelle, F; Fayoux, P; Froehlich, P; Garabédian, EN; Leboulanger, N; Lescanne, E; Marianowski, R; Marie, JP; Mom, T; Mondain, M; Nicollas, R; Roger, G; Teissier, N; Triglia, JM; Van Den Abbeele, T, 2010) |
| "The successful management of subglottic hemangioma with propranolol has been reported." | 3.76 | Management of infantile subglottic hemangioma: acebutolol or propranolol? ( Amedro, P; Bigorre, M; Blanchet, C; Mondain, M; Nicollas, R, 2010) |
| "A case of a 4-month-old girl with a subglottic haemangioma successfully treated with propranolol is reported." | 3.76 | A clue on the face... ( Spinks, J, 2010) |
| " She was given propranolol after her tracheotomy and had a significant reduction in her subglottic airway obstruction." | 3.76 | Propranolol in the management of airway infantile hemangiomas. ( Frieden, IJ; Maguiness, SM; Meyer, AK; Rosbe, KW; Suh, KY, 2010) |
| "There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol." | 3.75 | Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. ( Denoyelle, F; Enjolras, O; Garabedian, EN; Harris, R; Leboulanger, N; Roger, G, 2009) |
| "Infantile hemangioma is one of the most common benign tumors of infancy." | 2.72 | Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review. ( Ganeva, K; Nikiforova, L; Sapundzhiev, N; Shivachev, P, 2021) |
| "Although infantile hemangiomas are occasional benign vascular tumors that appear predominantly on the skin, 1-2% of patients may have airway lesions that can sometimes cause potentially life-threatening respiratory condi-tions." | 1.62 | [Cranio-facial-cervical and subglottic hemangioma with respiratory symptoms. A therapeutic emergency]. ( Arredondo Montero, J; Bardají Pascual, C; Molina Caballero, AY; Moreno Alfonso, JC; Pérez Martínez, A; Zubicaray Ugarteche, J, 2021) |
| "Propranolol is an effective, non-invasive treatment for life threatening infantile hemangiomas compressing the airway, should be used as a firstline treatment for subglottic hemangiomas when intervention is required." | 1.51 | A Life Threatening Subglottic and Mediastinal Hemangioma in an Infant. ( Gergin, O; Karabulut, B; Onder, SS, 2019) |
| "Subglottic hemangiomas are a rare presentation of infantile hemangiomas but with significant morbidity." | 1.48 | Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution. ( Azbell, C; Grunwaldt, L; Jabbour, N; McCormick, AA; Tarchichi, T, 2018) |
| "Subglottic hemangioma is a rare, potentially life threatening tumor of infancy which poses serious treatment challenges." | 1.36 | Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma. ( Baum, ED; Canadas, KT; Lee, S; Ostrower, ST, 2010) |
| "Subglottic haemangioma is a rare but potentially life threatening condition which requires intervention." | 1.35 | Successful treatment of isolated subglottic haemangioma with propranolol alone. ( Harper, J; Hartley, BE; Jephson, CG; Manunza, F; Mills, NA; Syed, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.13) | 18.7374 |
| 1990's | 1 (2.13) | 18.2507 |
| 2000's | 2 (4.26) | 29.6817 |
| 2010's | 37 (78.72) | 24.3611 |
| 2020's | 6 (12.77) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, Q | 1 |
| Hai, Y | 1 |
| Chen, S | 1 |
| Feng, N | 1 |
| Mo, Z | 1 |
| Wei, Y | 1 |
| Luo, Q | 1 |
| Huang, X | 1 |
| Fan, L | 1 |
| Chen, J | 1 |
| Xiang, W | 1 |
| D'Ambrosio, PD | 1 |
| Cardoso, PFG | 1 |
| Silva, PLD | 1 |
| Fernandes, PMP | 1 |
| Minamoto, H | 1 |
| Ganeva, K | 1 |
| Shivachev, P | 1 |
| Sapundzhiev, N | 1 |
| Nikiforova, L | 1 |
| Sun, X | 1 |
| Liu, X | 1 |
| Fang, Y | 1 |
| Li, W | 1 |
| Ma, Y | 1 |
| Liu, Y | 1 |
| Moreno Alfonso, JC | 1 |
| Molina Caballero, AY | 1 |
| Pérez Martínez, A | 1 |
| Arredondo Montero, J | 1 |
| Zubicaray Ugarteche, J | 1 |
| Bardají Pascual, C | 1 |
| Konstantinidou, S | 1 |
| Butler, CR | 1 |
| Hartley, B | 1 |
| Frauenfelder, C | 1 |
| McCormick, AA | 1 |
| Tarchichi, T | 1 |
| Azbell, C | 1 |
| Grunwaldt, L | 1 |
| Jabbour, N | 1 |
| Álvarez-Neri, H | 1 |
| Penchyna-Grub, J | 1 |
| Teyssier-Morales, G | 1 |
| Morera-Serna, E | 1 |
| Torre, C | 1 |
| Villamor, P | 1 |
| Liu, Z | 1 |
| Yeo, YH | 1 |
| Jackson, C | 1 |
| Trimble, K | 1 |
| Onder, SS | 1 |
| Gergin, O | 1 |
| Karabulut, B | 1 |
| Wang, HW | 1 |
| Zhang, N | 1 |
| Zhang, JL | 1 |
| Soldatskiĭ, IuL | 1 |
| Timofeeva, MIu | 1 |
| Koltukova, NP | 1 |
| Strygina, IuV | 1 |
| Gasparian, SF | 1 |
| Kislenko, OA | 1 |
| Lind, H | 1 |
| Zaharov, T | 1 |
| Godballe, C | 1 |
| Siegel, B | 1 |
| Mehta, D | 1 |
| Elluru, RG | 1 |
| Friess, MR | 1 |
| Richter, GT | 1 |
| Grimmer, JF | 1 |
| Darrow, DH | 1 |
| Shin, JJ | 1 |
| Perkins, JA | 2 |
| Krstulovic, C | 1 |
| Ibañez-Alcañiz, I | 1 |
| Alamar-Velázquez, A | 1 |
| López-Andreu, J | 1 |
| Evoli-Buselli, M | 1 |
| Li, XY | 1 |
| Wang, Y | 1 |
| Jin, L | 1 |
| Chen, JR | 1 |
| Hardison, S | 1 |
| Wan, W | 1 |
| Dodson, KM | 1 |
| Denoyelle, F | 4 |
| Leboulanger, N | 3 |
| Enjolras, O | 1 |
| Harris, R | 1 |
| Roger, G | 2 |
| Garabedian, EN | 4 |
| Jephson, CG | 2 |
| Manunza, F | 2 |
| Syed, S | 2 |
| Mills, NA | 1 |
| Harper, J | 1 |
| Hartley, BE | 2 |
| Laguda, B | 1 |
| Linward, J | 1 |
| Kennedy, H | 1 |
| Gholam, K | 1 |
| Glover, M | 1 |
| Giardini, A | 1 |
| Harper, JI | 2 |
| Maturo, S | 2 |
| Hartnick, C | 1 |
| Truong, MT | 2 |
| Chang, KW | 2 |
| Berk, DR | 1 |
| Heerema-McKenney, A | 1 |
| Bruckner, AL | 1 |
| Mistry, N | 1 |
| Tzifa, K | 1 |
| Blanchet, C | 1 |
| Nicollas, R | 2 |
| Bigorre, M | 1 |
| Amedro, P | 1 |
| Mondain, M | 2 |
| Rosbe, KW | 2 |
| Suh, KY | 1 |
| Meyer, AK | 2 |
| Maguiness, SM | 1 |
| Frieden, IJ | 2 |
| Messner, AH | 1 |
| Fayoux, P | 1 |
| Teissier, N | 1 |
| Cox, A | 2 |
| Van Den Abbeele, T | 1 |
| Carrabin, L | 1 |
| Couloigner, V | 1 |
| Triglia, JM | 1 |
| Ayari, S | 1 |
| Froehlich, P | 1 |
| Lescanne, E | 1 |
| Marianowski, R | 1 |
| Mom, T | 1 |
| Marie, JP | 1 |
| Canadas, KT | 1 |
| Baum, ED | 1 |
| Lee, S | 1 |
| Ostrower, ST | 1 |
| Guye, E | 1 |
| Chollet-Rivier, M | 1 |
| Schröder, D | 1 |
| Sandu, K | 1 |
| Hohlfeld, J | 2 |
| de Buys Roessingh, A | 2 |
| Peridis, S | 1 |
| Pilgrim, G | 1 |
| Athanasopoulos, I | 1 |
| Parpounas, K | 1 |
| Tse, SM | 1 |
| Kinane, TB | 1 |
| Hartnick, CJ | 1 |
| Blatt, J | 1 |
| Morrell, DS | 1 |
| Buck, S | 1 |
| Zdanski, C | 1 |
| Gold, S | 1 |
| Stavas, J | 1 |
| Powell, C | 1 |
| Burkhart, CN | 1 |
| Chun, YH | 1 |
| Moon, CJ | 1 |
| Yoon, JS | 1 |
| Kim, HH | 1 |
| Kim, JT | 1 |
| Lee, JS | 1 |
| Javia, LR | 1 |
| Zur, KB | 1 |
| Jacobs, IN | 1 |
| Raol, N | 1 |
| Metry, D | 1 |
| Edmonds, J | 1 |
| Chandy, B | 1 |
| Sulek, M | 1 |
| Larrier, D | 1 |
| Mahadevan, M | 1 |
| Cheng, A | 1 |
| Barber, C | 1 |
| Fischer, CJ | 1 |
| Giannoni, E | 1 |
| Truttmann, AC | 1 |
| Tolsa, JF | 1 |
| Chevallay, M | 1 |
| El Ezzi, O | 1 |
| Seneggen, E | 1 |
| Pauchard, JY | 1 |
| Gehri, M | 1 |
| Hauschild, M | 1 |
| Spinks, J | 1 |
| Durr, ML | 1 |
| Huoh, KC | 1 |
| Loizzi, M | 1 |
| De Palma, A | 1 |
| Pagliarulo, V | 1 |
| Quaranta, N | 1 |
| Tang, LX | 1 |
| Zhang, YM | 1 |
| Wang, GX | 1 |
| Bajaj, Y | 1 |
| Kapoor, K | 1 |
| Ifeacho, S | 1 |
| Albert, DM | 1 |
| Kelly, LA | 1 |
| Butcher, RW | 1 |
| Hawkins, J | 1 |
| Lewis, HD | 1 |
| Emmot, W | 1 |
| Vacek, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study[NCT00967226] | Phase 2 | 19 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to Serious adverse events with prednisolone, primarily temporary growth retardation, <5th percentile.) | ||
| A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma[NCT01072045] | Phase 2 | 50 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase II, Randomized, Double-Blind Comparison of Corticosteroid and Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)[NCT01074437] | Phase 2 | 9 participants (Actual) | Interventional | 2010-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of allergy/immunology AE per study arm (NCT00967226)
Timeframe: enrollment through study closeout or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Allergy/Immunology Events Propranolol | 1 |
| Allergy/Immunology Events Prednisolone | 1 |
Number of constitutional AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Constitutional AEs Propranolol | 2 |
| Constitutional AEs Prednisolone | 3 |
A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available. (NCT00967226)
Timeframe: 4-5 months after initiating therapy
| Intervention | mm squared (Mean) |
|---|---|
| Propranolol | 0.57 |
| Prednisolone | 0.63 |
Number of Dermatologic Adverse Events in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Dermatologic AEs Propranolol | 2 |
| Dermatologic AEs Prednisolone | 1 |
Number of Endocrinologic AEs (of which adrenal crisis does not overlap). (NCT00967226)
Timeframe: enrollment to close out or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Endocrine AEs Propranolol | 0 |
| Endocrinologic AEs Prednisolone | 7 |
Number of Gastrointestinal AEs in each arm (NCT00967226)
Timeframe: enrollment to study withdrawal or study close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Gastrointestinal AEs Propranolol | 6 |
| Gastrointestinal AEs Prednisolone | 6 |
Number of Growth and Development AEs in each study arm (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Growth/Developoment AEs Propranolol | 0 |
| Growth/Development AEs Prednisolone | 1 |
Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever) (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Infectious AEs Propranolol | 5 |
| Infectious AEs Prednisolone | 3 |
Number of Metabolic or Laboratory AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Metabolic/Laboratory AEs Propranolol | 1 |
| Metabolic/Laboratory AEs Prednisolone | 0 |
Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Serious Adverse Events (Number) |
|---|---|
| Number of Serious Adverse Events in Propranolol | 1 |
| Number of Serious Adverse Events in Prednisolone | 11 |
Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm (NCT00967226)
Timeframe: enrollment through study close out or withdrawal, up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Pulmonary/Respiratory AEs Propranolol | 14 |
| Pulmonary/Respiratory AEs Prednisolone | 4 |
Number of Vascular AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Vascular AEs Propranolol | 3 |
| Vascular AEs Prednisolone | 4 |
All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Events (Number) | |
|---|---|---|
| Adverse Events | Serious Adverse Events | |
| Overall Number of Adverse Events in Prednisolone | 30 | 11 |
| Overall Number of Adverse Events in Propranolol | 34 | 1 |
7 reviews available for propranolol and Laryngeal Neoplasms
| Article | Year |
|---|---|
Mediastinal and subglottic hemangioma in an infant: a case report and literature review.
Topics: Hemangioma; Humans; Infant; Laryngeal Neoplasms; Male; Mediastinum; Propranolol; Retrospective Studi | 2021 |
Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review.
Topics: Child; Hemangioma; Hemangioma, Capillary; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Propran | 2021 |
[Tiempo de respuesta terapéutica al propranolol sistémico en el manejo de hemangiomas subglóticos pediátricos: serie de casos y revisión de la literatura].
Topics: Administration, Oral; Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms | 2018 |
The use of propranolol in the treatment of subglottic hemangiomas: A literature review and meta-analysis.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Endoscopy; Hemangioma; Hum | 2016 |
Initial experience using propranolol as the sole treatment for infantile airway hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Magnetic Reson | 2010 |
A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemangioma; Humans; Infant; | 2011 |
Infantile haemangioma and β-blockers in otolaryngology.
Topics: Acebutolol; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Hemangioma; Humans; Infan | 2011 |
40 other studies available for propranolol and Laryngeal Neoplasms
| Article | Year |
|---|---|
Management of infantile subglottic hemangioma with T-tube placement and propranolol.
Topics: Hemangioma; Humans; Infant; Laryngeal Neoplasms; Propranolol; Treatment Outcome | 2022 |
[Applied value of color Doppler flow imaging in diagnosis of congenital subglottic haemangioma in infant].
Topics: Child; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Propranolol; Retrospective Studies; | 2021 |
[Cranio-facial-cervical and subglottic hemangioma with respiratory symptoms. A therapeutic emergency].
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Propranolol; Tr | 2021 |
Subglottic ectopic thymus mimicking airway haemangioma.
Topics: Hemangioma; Humans; Infant; Infant, Newborn; Laryngeal Neoplasms; Lymphatic Diseases; Propranolol; R | 2021 |
Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution.
Topics: Antineoplastic Agents; Combined Modality Therapy; Facial Neoplasms; Female; Hemangioma; Humans; Infa | 2018 |
Treatment failure with propranolol for subglottic haemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Laryngeal Neoplasms; | 2019 |
A Life Threatening Subglottic and Mediastinal Hemangioma in an Infant.
Topics: Female; Hemangioma; Hemangioma, Capillary; Humans; Infant; Laryngeal Neoplasms; Mediastinal Neoplasm | 2019 |
[A case of congenital subglottic hemangiomas].
Topics: Administration, Oral; Bronchoscopy; Female; Glottis; Hemangioma; Humans; Infant, Newborn; Laryngeal | 2013 |
[The effectiveness of propranolol therapy of subfold hemangioma in the children during the first year of life].
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Glottis; Hemangioma; Humans; | 2014 |
[Subglottic haemangioma].
Topics: Female; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Propranolol; Rare Di | 2014 |
Open airway surgery for subglottic hemangioma in the era of propranolol: Is it still indicated?
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Laryngeal Neoplasms; Lary | 2015 |
Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas.
Topics: Airway Obstruction; Endoscopy; Female; Hemangioma; Humans; Infant; Infant, Newborn; Laryngeal Neopla | 2015 |
[Fast response of subglottic haemangiomas to propranolol].
Topics: Child, Preschool; Female; Glottis; Hemangioma; Humans; Infant; Infant, Newborn; Laryngeal Neoplasms; | 2016 |
Role of oral propranolol in the treatment of infantile subglottic hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Glottis; Hemangioma; Humans; Infant; Infa | 2016 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Successful treatment of isolated subglottic haemangioma with propranolol alone.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glottis; | 2009 |
Propranolol for complicated infantile haemangiomas: a case series of 30 infants.
Topics: Adrenergic beta-Antagonists; Eyelid Neoplasms; Facial Neoplasms; Female; Follow-Up Studies; Glottis; | 2010 |
Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Antineoplastic Agents, Hormon | 2010 |
Propranolol may become first-line treatment in obstructive subglottic infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Laryngeal Neoplasms; Propranolol | 2010 |
Use of propranolol to treat multicentric airway haemangioma.
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Anti-Inflammatory Agents; Dexamethasone; Endoscopy; | 2010 |
Management of infantile subglottic hemangioma: acebutolol or propranolol?
Topics: Acebutolol; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administration Sched | 2010 |
Propranolol in the management of airway infantile hemangiomas.
Topics: Adrenal Cortex Hormones; Airway Obstruction; Combined Modality Therapy; Drug Therapy, Combination; F | 2010 |
Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Female; Hemangioma; Humans; I | 2010 |
Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience.
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Drug Resistance; Hemangioma; Humans; Infant; Infant | 2010 |
Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma.
Topics: Female; Follow-Up Studies; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; L | 2010 |
Propranolol treatment for subglottic haemangioma.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Laryngos | 2011 |
Initial experience using propranolol as an adjunctive treatment in children with aggressive recurrent respiratory papillomatosis.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Dysphonia; Female; Humans; Laryngeal Neop | 2011 |
β-blockers for infantile hemangiomas: a single-institution experience.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Drug Monitoring; Female; | 2011 |
Successful treatment of infantile subglottic hemangioma with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal Neo | 2012 |
Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery?
Topics: Cohort Studies; Female; Follow-Up Studies; Hemangioma; Hospitals, Pediatric; Humans; Immunohistochem | 2011 |
Propranolol for the treatment of subglottic hemangiomas.
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Male; Propranolol; Re | 2011 |
Treatment of subglottic hemangiomas with propranolol: initial experience in 10 infants.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Glottis; Hemangioma; Humans; Infant; Larynge | 2011 |
[Pediatrics].
Topics: Adrenergic beta-Agonists; Bacterial Infections; Breast Feeding; Enterocolitis, Necrotizing; Fever; G | 2012 |
A clue on the face...
Topics: Bronchoscopy; Diagnosis, Differential; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Lary | 2010 |
Airway hemangiomas in PHACE syndrome.
Topics: Aortic Coarctation; Bronchoscopy; Disease-Free Survival; Eye Abnormalities; Female; Follow-Up Studie | 2012 |
Propranolol as first-line treatment of a severe subglottic haemangioma.
Topics: Bronchoscopy; Constriction, Pathologic; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Pro | 2013 |
[Treatment of infantile subglottic hemangioma with oral propranolol].
Topics: Female; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Male; Propranolol; Treatment Outco | 2012 |
Great Ormond Street Hospital treatment guidelines for use of propranolol in infantile isolated subglottic haemangioma.
Topics: Constriction, Pathologic; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Practice Guideli | 2013 |
Studies on cyclic AMP metabolism in human epidermoid carcinoma (HEp-2) cells.
Topics: Adenosine; Adenylyl Cyclases; Adrenocorticotropic Hormone; Carcinoma, Squamous Cell; Cell Line; Cycl | 1975 |
Vasodepressive carotid sinus hypersensitivity with head and neck malignancy: treatment with propranolol.
Topics: Carcinoma, Squamous Cell; Carotid Sinus; Humans; Hypotension; Laryngeal Neoplasms; Male; Middle Aged | 1991 |